...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: Validation through agonist and antagonist docking
【24h】

Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: Validation through agonist and antagonist docking

机译:使用分段同源物预测GPCR的结构并应用于人CCR5趋化因子受体:通过激动剂和拮抗剂对接进行验证

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

This article describes the construction and validation of a three-dimensional model of the human CC chemokine receptor 5 (CCR5) receptor using multiple homology modeling. A new methodology is presented where we built each secondary structural model of the protein separately from distantly related homologs of known structure. The reliability of our approach for G-protein coupled receptors was assessed through the building of the human C-X-C chemokine receptor type 4 (CXCR4) receptor of known crystal structure. The models are refined using molecular dynamics simulations and energy minimizations using CHARMM, a classical force field for proteins. Finally, docking models of both the natural agonists and the antagonists of the receptors CCR5 and CXCR4 are proposed. This study explores the possible binding process of ligands to the receptor cavity of chemokine receptors at molecular and atomic levels. We proposed few crucial residues in receptors binding to agonist/antagonist for further validation through experimental analysis. In particular, our study provides better understanding of the blockage mechanism of the chemokine receptors CCR5 and CXCR4, and may help the identification of new lead compounds for drug development in HIV infection, inflammatory diseases, and cancer metastasis.
机译:本文介绍了使用多重同源性建模的人CC趋化因子受体5(CCR5)受体的三维模型的构建和验证。提出了一种新的方法,其中我们从已知结构的远缘同源物分别构建了蛋白质的每个二级结构模型。通过构建已知晶体结构的人类C-X-C趋化因子受体4型(CXCR4)受体,我们评估了G蛋白偶联受体方法的可靠性。使用分子动力学模拟和使用CHARMM(蛋白质的经典力场)的能量最小化对模型进行完善。最后,提出了天然激动剂和受体CCR5和CXCR4的拮抗剂的对接模型。这项研究探索了分子和原子水平上配体与趋化因子受体受体腔的可能结合过程。我们提出了受体中与激动剂/拮抗剂结合的关键残基,以通过实验分析进一步验证。特别是,我们的研究提供了对趋化因子受体CCR5和CXCR4阻断机制的更好理解,并可能有助于鉴定用于HIV感染,炎性疾病和癌症转移的药物开发的新的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号